Cargando…

Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar

BACKGROUND: Artemisinins are the most effective anti-malarial drugs for uncomplicated and severe Plasmodium falciparum malaria. However, widespread artemisinin resistance in the Greater Mekong Region of Southeast Asia is threatening the possibility to control and eliminate malaria. This work aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lohy Das, Jesmin Permala, Kyaw, Myat P., Nyunt, Myat H., Chit, Khin, Aye, Kyin H., Aye, Moe M., Karlsson, Mats O., Bergstrand, Martin, Tarning, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865368/
https://www.ncbi.nlm.nih.gov/pubmed/29566683
http://dx.doi.org/10.1186/s12936-018-2278-5
_version_ 1783308671215730688
author Lohy Das, Jesmin Permala
Kyaw, Myat P.
Nyunt, Myat H.
Chit, Khin
Aye, Kyin H.
Aye, Moe M.
Karlsson, Mats O.
Bergstrand, Martin
Tarning, Joel
author_facet Lohy Das, Jesmin Permala
Kyaw, Myat P.
Nyunt, Myat H.
Chit, Khin
Aye, Kyin H.
Aye, Moe M.
Karlsson, Mats O.
Bergstrand, Martin
Tarning, Joel
author_sort Lohy Das, Jesmin Permala
collection PubMed
description BACKGROUND: Artemisinins are the most effective anti-malarial drugs for uncomplicated and severe Plasmodium falciparum malaria. However, widespread artemisinin resistance in the Greater Mekong Region of Southeast Asia is threatening the possibility to control and eliminate malaria. This work aimed to evaluate the pharmacokinetic and pharmacodynamic properties of artesunate and its active metabolite, dihydroartemisinin, in patients with sensitive and resistant falciparum infections in Southern Myanmar. In addition, a simple nomogram previously developed to identify artemisinin resistant malaria infections was evaluated. METHODS: Fifty-three (n = 53) patients were recruited and received daily oral artesunate monotherapy (4 mg/kg) for 7 days. Frequent artesunate and dihydroartemisinin plasma concentration measurements and parasite microscopy counts were obtained and evaluated using nonlinear mixed-effects modelling. RESULTS: The absorption of artesunate was best characterized by a transit-compartment (n = 3) model, followed by one-compartment disposition models for artesunate and dihydroartemisinin. The drug-dependent parasite killing effect of dihydroartemisinin was described using an Emax function, with a mixture model discriminating between artemisinin sensitive and resistant parasites. Overall, 56% of the studied population was predicted to have resistant malaria infections. Application of the proposed nomogram to identify artemisinin-resistant malaria infections demonstrated an overall sensitivity of 90% compared to 55% with the traditional day-3 positivity test. CONCLUSION: The pharmacokinetic-pharmacodynamic properties of artesunate and dihydroartemisinin were well-characterized with a mixture model to differentiate between drug sensitive and resistant infections in these patients. More than half of all patients recruited in this study had artemisinin-resistant infections. The relatively high sensitivity of the proposed nomogram highlights its potential clinical usefulness.
format Online
Article
Text
id pubmed-5865368
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58653682018-03-27 Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar Lohy Das, Jesmin Permala Kyaw, Myat P. Nyunt, Myat H. Chit, Khin Aye, Kyin H. Aye, Moe M. Karlsson, Mats O. Bergstrand, Martin Tarning, Joel Malar J Research BACKGROUND: Artemisinins are the most effective anti-malarial drugs for uncomplicated and severe Plasmodium falciparum malaria. However, widespread artemisinin resistance in the Greater Mekong Region of Southeast Asia is threatening the possibility to control and eliminate malaria. This work aimed to evaluate the pharmacokinetic and pharmacodynamic properties of artesunate and its active metabolite, dihydroartemisinin, in patients with sensitive and resistant falciparum infections in Southern Myanmar. In addition, a simple nomogram previously developed to identify artemisinin resistant malaria infections was evaluated. METHODS: Fifty-three (n = 53) patients were recruited and received daily oral artesunate monotherapy (4 mg/kg) for 7 days. Frequent artesunate and dihydroartemisinin plasma concentration measurements and parasite microscopy counts were obtained and evaluated using nonlinear mixed-effects modelling. RESULTS: The absorption of artesunate was best characterized by a transit-compartment (n = 3) model, followed by one-compartment disposition models for artesunate and dihydroartemisinin. The drug-dependent parasite killing effect of dihydroartemisinin was described using an Emax function, with a mixture model discriminating between artemisinin sensitive and resistant parasites. Overall, 56% of the studied population was predicted to have resistant malaria infections. Application of the proposed nomogram to identify artemisinin-resistant malaria infections demonstrated an overall sensitivity of 90% compared to 55% with the traditional day-3 positivity test. CONCLUSION: The pharmacokinetic-pharmacodynamic properties of artesunate and dihydroartemisinin were well-characterized with a mixture model to differentiate between drug sensitive and resistant infections in these patients. More than half of all patients recruited in this study had artemisinin-resistant infections. The relatively high sensitivity of the proposed nomogram highlights its potential clinical usefulness. BioMed Central 2018-03-23 /pmc/articles/PMC5865368/ /pubmed/29566683 http://dx.doi.org/10.1186/s12936-018-2278-5 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lohy Das, Jesmin Permala
Kyaw, Myat P.
Nyunt, Myat H.
Chit, Khin
Aye, Kyin H.
Aye, Moe M.
Karlsson, Mats O.
Bergstrand, Martin
Tarning, Joel
Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar
title Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar
title_full Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar
title_fullStr Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar
title_full_unstemmed Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar
title_short Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar
title_sort population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in southern myanmar
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865368/
https://www.ncbi.nlm.nih.gov/pubmed/29566683
http://dx.doi.org/10.1186/s12936-018-2278-5
work_keys_str_mv AT lohydasjesminpermala populationpharmacokineticandpharmacodynamicpropertiesofartesunateinpatientswithartemisininsensitiveandresistantinfectionsinsouthernmyanmar
AT kyawmyatp populationpharmacokineticandpharmacodynamicpropertiesofartesunateinpatientswithartemisininsensitiveandresistantinfectionsinsouthernmyanmar
AT nyuntmyath populationpharmacokineticandpharmacodynamicpropertiesofartesunateinpatientswithartemisininsensitiveandresistantinfectionsinsouthernmyanmar
AT chitkhin populationpharmacokineticandpharmacodynamicpropertiesofartesunateinpatientswithartemisininsensitiveandresistantinfectionsinsouthernmyanmar
AT ayekyinh populationpharmacokineticandpharmacodynamicpropertiesofartesunateinpatientswithartemisininsensitiveandresistantinfectionsinsouthernmyanmar
AT ayemoem populationpharmacokineticandpharmacodynamicpropertiesofartesunateinpatientswithartemisininsensitiveandresistantinfectionsinsouthernmyanmar
AT karlssonmatso populationpharmacokineticandpharmacodynamicpropertiesofartesunateinpatientswithartemisininsensitiveandresistantinfectionsinsouthernmyanmar
AT bergstrandmartin populationpharmacokineticandpharmacodynamicpropertiesofartesunateinpatientswithartemisininsensitiveandresistantinfectionsinsouthernmyanmar
AT tarningjoel populationpharmacokineticandpharmacodynamicpropertiesofartesunateinpatientswithartemisininsensitiveandresistantinfectionsinsouthernmyanmar